Optimizing pneumococcal prevention in South African older adults: Cost-effectiveness of PCV20 versus PPSV23 in the context of HIV-associated risk
ABSTRACT Pneumococcal disease remains a major cause of morbidity and mortality among older adults in South Africa, particularly among people living with HIV. Evidence on the cost-effectiveness of Prevnar 20 (PCV20) vs. Pneumovax 23 (PPSV23) vaccine in this setting remains limited. This study was conducted to evaluate t...